Member Info for LovableLumax

*Touk, obviously it’s All good to change your view.

Too, obviously it’s All good to change your view. I assume the view you say have taken is now different from the one earlier today? What made you change your mind? A reminder -

The first figure is AVA6000, the second is the doxorubicin payload. The most obvious conclusion is that it is an error on a poorly proof read slide and should be 385/260 as above.

Then why have an additional arrow below and not just 10 on that dose. Clearly it’s different and 200 isn’t in brackets so it suggests it’s the AVA6000 dose rather than dox equivalent.

You want a P1b update after probably 2 months of dosing. Really? They’re clearly waiting on something (could be a conference or something material) to tell us the dosing regimes so until that’s happened we won’t get an update IMO and it’d be premature anyway,

I suspect Coris close to being sold which will be a large haircut but should bring £3m-4m in which I suspect gets the audit signed off. They will then concentrate on signing deals and as the P1b data comes in those under NDA will have access and I'm sure we will have options aplenty. Main thing is the BOD knows they're gone if they raise cash down here.

Pharma spending billions and billions and ADC and PDCs so delivering these more effectively they think will be around for a good while hence they’re spending all that cash

From what I can see the issue mirriad has is it has had proof of concept on a lot for a while. The issue remains monetising at scale. While that happens all these piddly campaigns barely touch costs so cash burn remains high.

We had all this noise and have worked with Pepsi co, P&G and other large brands for years but until programmatic fully rolled out revenues will struggle and we know what the means early in Q2, begging bowl. They had more cash last year and promised programmatic in 2 months (before end of June) yet the auditor wanted cash to see them through 12 months. Same will surely happen again. Question is will they get strategic investors or will they have to give another large discount? IIs usually want their pound of flesh but I could be wrong and have been many times!! Should know by end of next month or so.

LOTM you’re funny as. You think I give a toss what you think?! This board is your little fiefdom which is as funny as it is sad.

I’m not looking for anyone’s trust but am merely giving a balanced appraisal unlike you. I’ll leave it there.

LOTM that’s rich re credibility!! You hVe no self awareness at all. Yes I lost a fair whack here although made some back shorting it. You should get a professional investor account as shorting, IPOs and raises will be open to you.

I’m not bitter but don’t want others making the same mistake. Most of my predictions have come to pass here. Remember last April when you told others to buy at over 2p and here we are circa 1/10th of that and you were on here grovelling.

Get a grip.

If I was a bitter man I’d want others to lose money here, that would make some feel better but not me.

Check my last posts and all makes sense.

Yeah I lost a fair whack here when well over 5p let alone 1p!!

I’m offering balance. No? It could fly if turned a corner and a small raise at a premium. On the other hand. We’ll soon know.

Flightman you are fragile. I think you'll find my posts have a lot more balance than all else. Anyone holding should have done some basic research so my musings wouldn't be new info to them so not been a catalyst for selling.

Unless Mirriad has significantly increased H1 revenues the question will be how much booked revenue can they show the auditor to reduce the amount needed for audit sign off. The auditor won't simply take Mirriad's word that revenue will be delivered especially as it has missed every financial guide it has ever published. H1 is always slow so cash burn high and they only had £4.8m at YE. This was from June 7 RNS -

Cash holding at the end of April was approximately £3.9m, prior to the receipt of c. £6.3m net proceeds from the placing and retail offer.

Now given MIRI was saying programmatic launch was imminent and it guided £4m revenue (got 1/4 of that) they still needed a large cash injection. As at end of April this year I suspect there will be at least £1m less cash than last year so it'll be imperative they have lots of booked revenue (signed contracts) and not pie in the sky nonsense. If not another hefty raise en route.

On the flip side MIRI may have lots of booked revenue and may only need a small amount and this could be injected through strategic partners or investors and at a premium. If so I suspect this will quickly be 1p+. We should have a very good idea latest early May if not before.

This is ridiculous. Labour is full of liars who renege on their promises. Tories exactly the same. Starmer more a Tory than many Tory MPs!

Anyway, really hope some positive news drops soon as we need to move into a new range. Surely CC can line up IIs to take shares, TR1s would be immense.

Mirriad had £6.1m Dec 31st 2023 which was enough cash to end of August too. They worked on a raise in April all the whole Phevs and LOTM were pumping and got others to buy. They couldn’t see the 40% discounted placing coming.

Mirriad has reduced costs but still the £4.8m takes them again to August. Who knows unlike last time all these LinkedIn posts may mean a large uptick in revenue and all is well.

Bizarre the only TR1s since the raise have been sells. Surely these guys should be buying not selling. We’ll see

TripleLift signed a deal with mirriad which mirriad published in a regulated RNS. Only a matter of weeks later mirriad works on a raise at a 40% discount as it only had I think £3.3m in cash and needed money for audit sign off. The raise round were in April. I bet mirriad has less money now. Companies sign deals and advertise partnerships in good faith, they aren’t privy to material news and won’t know if mirriad gets the begging bowl out.

Maybe I’m wrong as mirriad has lots of cash coming in and H1 has suddenly been superb.

These deals are not expected to generate material revenues hence no RNS.

In May mirriad said programmatic would be ready by end of June last year, in Sept they said ready before end of year and here we are end of Q1 and no news. Next news could be a rampy RNS before begging bowl makes an appearance. Given mirriad has always missed any guidance how much cash will the auditor demand they have on their balance sheet to satisfy them for 12 months from sign off (end of June).

That’s why no TR1s for buys only sells.

Bentley, I for one expect some rampy RNSs soon given they will likely need to raise. Last year they had some rampy interviews with Stephan and then the TripleLift RNS as the big programmatic partner and then told us it would be launched by end of June. The raise was worked on soon after the RNS and dropped early May. We are a month ahead of that but with less cash. Unless they have some decent orders (that the audit can see) the begging bowl comes out again. If they’ve turned a corner they could get the cash at a premium or a loan but if more jam tomorrow more pain. We should know with 6 or 7 weeks.

The half life of exatecan needed to be extended and has been over 6 fold. AVA6000 didn’t need tweaking as evidenced by the biopsies which were taken 24 hours later. They’d have had a good idea before dosing began if changes were needed which is why animal models are so important. The early signs of efficacy also illustrate this, not surprising when getting 100 fold more into tumour than plasma. PFS for SGC data next Q should be exciting.

Https://x.com/asininitybeyond/status/1900818524450238973?s=46

Myles’ take -

"Away from STS, they are already beating SGC’s PFS."

The most important takeaway from the various important info released by #AVCT over the last week. Really sick, heavily pre-treated patients with salivary gland cancer being treated with AVA6000 in the Phase 1a study have already enjoyed a median progression-free survival greater than they could have received from any other currently marketed drug.

And to note:

- That median PFS beat is only going to increase, as most patients in the trial are still under follow-up;

- In the registrational trial, patients will have undergone fewer prior treatments on average, thus increasing likelihood of response (and consequently, increasing the study's median PFS);

- Patients being treated with AVA6000 are all the while enjoying a MUCH better quality of life due to negligible side-effects (relative to conventional chemo), a crucial USP that should always be reiterated.

Most investors who have carried our proper DD will appreciate that #AVA6000 receiving accelerated approval for the salivary gland cancer indication, is pretty much a shoe in.

Avacta - especially at sub 40p! - remains a 100 bagger lying in plain sight.

The Dx venture and Heights debacle, although devasting (likely will have halved the long-term upside deu to dilution, once they have both been wholly removed from the equation), have by no means been catastrophic.

It will be looked back on as a painful and needless two and a half year transitory period. Fortunately, the pre | CISION platform has outshone all expectations by such an extent, that the 100 bagger proposition remains intact. The share count will likely have more than doubled, but the intrinsic value has increased by many multiples over the same period.

AVA6000 (both in-house revenues from SGC commencing hopefully in 2027; and from out-licensing for other indications - notably STS, TNBC) will put Avacta on a stable financial footing...

And AVA6103 changes the game completely.

"The Company has seen a dramatic increase in therapeutic index in preclinical models, suggesting that AVA6103 could have an unprecedented safety profile in the clinic. AVA6103 has the potential to treat hundreds of thousands of patients with the broad use of the topo I drug class and over 90% of solid tumors expressing FAP."

Of course those under NDA will have access to the data as it emerges